Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727928 | 1.00 | KMT2A (0.53) | KMT2AGAAADORA1ADORA2APDPK1 | |
| SCHEMBL7926347 | 0.81 | ADORA1 (0.48) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL31207340 | 0.78 | ADORA1 (0.46) | KMT2AGAAADORA1ADORA2APDPK1 | |
| SCHEMBL30445560 | 0.78 | ADORA1 (0.46) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL10884409 | 0.78 | KMT2A (0.46) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL12525866 | 0.78 | ADORA1 (0.46) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL1553593 | 0.78 | ADORA1 (0.46) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL22239632 | 0.76 | ADORA1 (0.44) | KMT2AGAAADORA1ADORA2AKDM4E | |
| SCHEMBL29768213 | 0.75 | PDPK1 (0.46) | GAAADORA1ADORA2APDPK1AURKA | |
| SCHEMBL26675355 | 0.75 | PDPK1 (0.46) | GAAADORA1ADORA2APDPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9486892-B2 | Polishing composition | FUJIMI INCORPORATED (JP) | 2016-11-08 | — | — | US | claimed |
| US-11992914-B2 | Polishing composition, polishing method, and method for producing substrate | FUJIMI INCORPORATED (JP) | 2024-05-28 | — | — | US | disclosed |
| WO-2023162551-A1 | METHOD FOR PRODUCING PLATED SHAPED ARTICLE | 東京応化工業株式会社 | 2023-08-31 | — | — | WO | disclosed |
| CN-110317573-B | Polishing composition, method for producing same, and magnetic polishing method | 福吉米株式会社 | 2022-07-15 | — | — | CN | disclosed |
| US-11339310-B2 | Polishing composition | FUJIMI INCORPORATED | 2022-05-24 | — | — | US | disclosed |
| US-20220055180-A1 | POLISHING COMPOSITION, POLISHING METHOD, AND METHOD FOR PRODUCING SUBSTRATE | FUJIMI INCORPORATED (JP) | 2022-02-24 | — | — | US | disclosed |
| CN-111919174-A | Method for producing plated molded article | 东京应化工业株式会社 | 2020-11-10 | — | — | CN | disclosed |
| EP-3124570-B1 | POLISHING COMPOSITION | FUJIMI INC (JP) | 2020-09-09 | — | — | EP | disclosed |
| CN-111574959-A | Polishing composition and polishing method | ＡＧＣ株式会社 | 2020-08-25 | — | — | CN | disclosed |
| US-20200263056-A1 | POLISHING COMPOSITION AND POLISHING METHOD | AGC Inc. (JP) | 2020-08-20 | — | — | US | disclosed |
| US-7524845-B2 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| WO-2008147822-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2007002293-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-4366231-A | Photographic material containing a stabilizer, a process for its production, a development process, new pyrazoles, a process for their production and intermediate products | AGFA GEVAERT AKTIENGESELLSCHAFT (DE) | 1982-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058341-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | KMT2A 3304/4885GAA 3352/4885ADORA1 238/4885 |
| US-20070010524-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | KMT2A 3304/4885GAA 3352/4885ADORA1 238/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | KMT2A 1124/4885GAA 1969/4885ADORA1 699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.